Effect of Carvedilol on Heart function

Evaluation of Carvedilol effect on LV function in patients treated with Herceptin due to breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015062922968N1

Enrollment

Registered

2015-09-16

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: ":Intervention group: " Tab Carvedilol 6/25 mg bid for 1 year. Intervention 2: Control group: Nothing.

Treatment - Drugs

":Intervention group: " Tab Carvedilol 6/25 mg bid for 1 year

Control group: Nothing

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: inclusion criteria: all of patient with breast cancer candidate for Herceptin therapy without attention to previous chemotherapy that have Ejection Fraction >50% and normal diastolic function or mild dysfunction exclusion criteria:patient who have contraindication for Carvedilol;grade 2or 3 AV block; Heart rate <50;systolic blood pressure<90;Asthma;chronic obstructive pulmonary disease ;liver cirrhosis;psoriasis; peripheral vascular disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Left ventriculare dysfunction. Timepoint: Before chemotherapy and 3-6-12 month after thet. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElmira Aghaee

Ekbatan Hospital

e.aghaeei@edu.umsha.ac.ir+98 81 3825 1244

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026